title: To test or not to test?
abstract: The use of genetic tests to improve diagnosis and to screen out potential non-responders to costly biologic therapies would seem like a prudent investment, but the practice is far from mainstream. To payers, the issue is more than black and white.
authors: Ed
authors: E
authors: Silverman